search
Back to results

Effect of Budesonide on Exhaled Nitric Oxide in Asthmatic Children

Primary Purpose

Asthma

Status
Completed
Phase
Phase 4
Locations
United States
Study Type
Interventional
Intervention
Nebulized Budesonide
Nitric Oxide Analyzer
Sponsored by
AAADRS Clinical Research Center
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Asthma

Eligibility Criteria

4 Years - 6 Years (Child)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Asthma diagnosis previously for 6 months
  • Past asthma medication without change for previous 6 months
  • Increased NO levels and ability to perform maneuver
  • ICF signed by parents

Exclusion Criteria:

  • Systemic steroids in past 60 days,inhaled/nebulized steroids in past 4 weeks
  • Hospitalization within 3 months
  • Upper or lower airways active infection or cigarette smoke direct exposure
  • Use of other asthma medications other than bronchodilators one month prior and during the trial
  • Noncompliance

Sites / Locations

  • AAADRS Clinical Research Center

Arms of the Study

Arm 1

Arm Type

Active Comparator

Arm Label

A

Arm Description

Nebulized budesonide

Outcomes

Primary Outcome Measures

Exhaled breath nitric oxide pre- to post treatment

Secondary Outcome Measures

Spirometry with peak flow measurements and daily diary scores

Full Information

First Posted
August 28, 2007
Last Updated
January 22, 2009
Sponsor
AAADRS Clinical Research Center
Collaborators
AstraZeneca
search

1. Study Identification

Unique Protocol Identification Number
NCT00522782
Brief Title
Effect of Budesonide on Exhaled Nitric Oxide in Asthmatic Children
Official Title
Phase IV Study of the Effect of Nebulized Budesonide on Exhaled Nitric Oxide in Children, Four to Six Years of Age, With Asthma
Study Type
Interventional

2. Study Status

Record Verification Date
January 2009
Overall Recruitment Status
Completed
Study Start Date
August 2007 (undefined)
Primary Completion Date
December 2008 (Actual)
Study Completion Date
January 2009 (Actual)

3. Sponsor/Collaborators

Name of the Sponsor
AAADRS Clinical Research Center
Collaborators
AstraZeneca

4. Oversight

Data Monitoring Committee
Yes

5. Study Description

Brief Summary
To study the improvement in airway inflammation in children with asthma non-invasively with exhaled breath NO, a marker of inflammation, after therapy with nebulized budesonide as 0.5mg daily.
Detailed Description
Comparisons will be made before and after 2 week therapy of nebulized budesonide in children not on prior anti-inflammatory medications.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Asthma

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 4
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
16 (Actual)

8. Arms, Groups, and Interventions

Arm Title
A
Arm Type
Active Comparator
Arm Description
Nebulized budesonide
Intervention Type
Drug
Intervention Name(s)
Nebulized Budesonide
Other Intervention Name(s)
Pulmicort Respules 0.5mg/2ml nebulized
Intervention Description
Pulmicort Respules 0.5mg/2cc
Intervention Type
Device
Intervention Name(s)
Nitric Oxide Analyzer
Other Intervention Name(s)
Niox NO analyzer
Intervention Description
Niox NO analyzer
Primary Outcome Measure Information:
Title
Exhaled breath nitric oxide pre- to post treatment
Time Frame
two weeks
Secondary Outcome Measure Information:
Title
Spirometry with peak flow measurements and daily diary scores
Time Frame
two weeks

10. Eligibility

Sex
All
Minimum Age & Unit of Time
4 Years
Maximum Age & Unit of Time
6 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Asthma diagnosis previously for 6 months Past asthma medication without change for previous 6 months Increased NO levels and ability to perform maneuver ICF signed by parents Exclusion Criteria: Systemic steroids in past 60 days,inhaled/nebulized steroids in past 4 weeks Hospitalization within 3 months Upper or lower airways active infection or cigarette smoke direct exposure Use of other asthma medications other than bronchodilators one month prior and during the trial Noncompliance
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Miguel J Lanz, MD
Organizational Affiliation
Principal Investigator
Official's Role
Principal Investigator
Facility Information:
Facility Name
AAADRS Clinical Research Center
City
Coral Gables
State/Province
Florida
ZIP/Postal Code
33134
Country
United States

12. IPD Sharing Statement

Learn more about this trial

Effect of Budesonide on Exhaled Nitric Oxide in Asthmatic Children

We'll reach out to this number within 24 hrs